rs587780100

Variant summary

Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong

The NM_002485.5(NBN):​c.698_701delAACA​(p.Lys233fs) variant causes a frameshift, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000105 in 1,611,606 control chromosomes in the GnomAD database, with no homozygous occurrence. 1/1 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.

Frequency

Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00011 ( 0 hom. )

Consequence

NBN
NM_002485.5 frameshift, splice_region

Scores

Not classified

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:14O:1

Conservation

PhyloP100: 7.59
Variant links:
Genes affected
NBN (HGNC:7652): (nibrin) Mutations in this gene are associated with Nijmegen breakage syndrome, an autosomal recessive chromosomal instability syndrome characterized by microcephaly, growth retardation, immunodeficiency, and cancer predisposition. The encoded protein is a member of the MRE11/RAD50 double-strand break repair complex which consists of 5 proteins. This gene product is thought to be involved in DNA double-strand break repair and DNA damage-induced checkpoint activation. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 16 ACMG points.

PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 8-89971173-CTGTT-C is Pathogenic according to our data. Variant chr8-89971173-CTGTT-C is described in ClinVar as [Pathogenic]. Clinvar id is 127878.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-89971173-CTGTT-C is described in Lovd as [Likely_pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
NBNNM_002485.5 linkuse as main transcriptc.698_701delAACA p.Lys233fs frameshift_variant, splice_region_variant 6/16 ENST00000265433.8 NP_002476.2 O60934

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
NBNENST00000265433.8 linkuse as main transcriptc.698_701delAACA p.Lys233fs frameshift_variant, splice_region_variant 6/161 NM_002485.5 ENSP00000265433.4 O60934

Frequencies

GnomAD3 genomes
AF:
0.0000197
AC:
3
AN:
152106
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000200
AC:
5
AN:
250094
Hom.:
0
AF XY:
0.00000740
AC XY:
1
AN XY:
135224
show subpopulations
Gnomad AFR exome
AF:
0.0000620
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000266
Gnomad OTH exome
AF:
0.000165
GnomAD4 exome
AF:
0.000114
AC:
167
AN:
1459500
Hom.:
0
AF XY:
0.000105
AC XY:
76
AN XY:
726074
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.000148
Gnomad4 OTH exome
AF:
0.0000498
GnomAD4 genome
AF:
0.0000197
AC:
3
AN:
152106
Hom.:
0
Cov.:
32
AF XY:
0.00
AC XY:
0
AN XY:
74290
show subpopulations
Gnomad4 AFR
AF:
0.0000241
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000294
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000712
Hom.:
0
Bravo
AF:
0.0000340

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:14Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Microcephaly, normal intelligence and immunodeficiency Pathogenic:6Other:1
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpAug 03, 2018Variant summary: NBN c.698_701delAACA (p.Lys233SerfsX5) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 2e-05 in 252006 control chromosomes (gnomAD). The variant, c.698_701delAACA, has been reported in the literature in individuals affected with Hereditary Breast and Ovarian Cancer and Nijmegen Breakage Syndrome (Varon_1998, Gass_2017, Ramus_2015, Li_2015, Susswein_2016). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpDec 21, 2023This sequence change creates a premature translational stop signal (p.Lys233Serfs*5) in the NBN gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NBN are known to be pathogenic (PMID: 9590180, 16415040). This variant is present in population databases (rs587780100, gnomAD 0.007%). This premature translational stop signal has been observed in individual(s) with Nijmegen breakage syndrome (NBS), and breast/ovarian cancer (PMID: 9590180, 15474156, 26315354, 26534844). This variant is also known as 698del4. ClinVar contains an entry for this variant (Variation ID: 127878). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoMar 05, 2015- -
Pathogenic, no assertion criteria providedclinical testingNatera, Inc.Nov 02, 2020- -
Pathogenic, no assertion criteria providedliterature onlyOMIMMay 01, 1998- -
Pathogenic, criteria provided, single submitterclinical testingGenome-Nilou LabNov 07, 2021- -
not provided, no classification providedliterature onlyGeneReviews-- -
not provided Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenApr 01, 2024NBN: PVS1, PS4:Moderate, PM2:Supporting -
Pathogenic, criteria provided, single submitterclinical testingGeneDxSep 27, 2023Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Also known as NBS1 698del4; This variant is associated with the following publications: (PMID: 9590180, 26681312, 24072268, 29915322, 31948886, 26315354, 26534844, 23149842, 27038244, 28374160, 28152038, 30043523, 29961768, 29625052, 26689913, 35626031, 34326862, 33804961, 32427313, 29922827, 32885271, 32338768, 28888541, 36451132, 36623239, 15474156) -
Pathogenic, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoMay 10, 2024The NBN c.698_701del (p.Lys233Serfs*5) variant alters the translational reading frame of the NBN mRNA and causes the premature termination of NBN protein synthesis. This variant has been reported in the published literature in reported in the biallelic state in multiple individuals with Nijmegen breakage syndrome (PMID 9590180 (1998), 10799436 (2000), 15474156 (2004)), as well as in the heterozygous state in multiple individuals with prostate cancer (PMID: 29915322 (2018)), pancreatic cancer (PMID: 29961768 (2019)), lung cancer (PMID: 26681312 (2015)), ovarian cancer (PMID: 26315354 (2015), PMID: 28888541 (2017)), and breast cancer and skin cancers (PMID: 28374160 (2017), 30043523 (2018)). The frequency of this variant in the general population, 0.000065 (2/30740 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is consistent with pathogenicity. Based on the available information, this variant is classified as pathogenic. -
Aplastic anemia;C0023449:Acute lymphoid leukemia;C0398791:Microcephaly, normal intelligence and immunodeficiency Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsJan 07, 2022- -
Aplastic anemia Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsMar 25, 2024- -
NBN-related disorder Pathogenic:1
Pathogenic, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesSep 13, 2024The NBN c.698_701delAACA variant is predicted to result in a frameshift and premature protein termination (p.Lys233Serfs*5). This variant has been reported in a patient with Nijmemgen breakage syndrome (Varon et al. 1998. PubMed ID: 9590180) and in individuals with various cancers, including breast and skin, prostate, or ovarian cancers (for example, Gass et al. 2017. PubMed ID: 28374160; Supplementary Table, Lerner-Ellis. 2020. PubMed ID: 32885271; Table S7, Lilyquist. 2017. PubMed ID: 28888541). This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD, and has been interpreted as pathogenic in ClinVar. Frameshift variants in NBN are expected to be pathogenic. This variant is interpreted as pathogenic. -
Malignant tumor of breast Pathogenic:1
Pathogenic, no assertion criteria providedclinical testingDepartment of Pathology and Laboratory Medicine, Sinai Health System-The NBN p.Lys233SerfsX5 variant was identified in 2 of 7792 proband chromosomes (frequency: 0.00026) from individuals or families with hereditary breast and ovarian cancer (Li_2015, Ramus_2015). The variant was also identified in dbSNP (ID: rs587780100) as “With Pathogenic allele”, ClinVar (as pathogenic by GeneDx, Ambry Genetics, University of Chicago, Invitae, Color Genomics, OMIM and GeneReviews), Clinvitae (3x as in ClinVar), LOVD 3.0, and Zhejiang Colon Cancer Database. The variant was not identified in Cosmic database. The variant was identified in control databases in 5 of 245144 chromosomes at a frequency of 0.00002 (Genome Aggregation Database Feb 27, 2017). It was observed in the following populations: African in 1 of 15226 chromosomes (freq: 0.000066), European (Non-Finnish) in 4 of 111062 chromosomes (freq: 0.000036), but it was not observed in the Ashkenazi Jewish, East Asian, European (Finnish), Latino, Other, and South Asian populations. The variant has been reported in families with Nijmegen Breakage Syndrome as well as in individuals with hereditary breast and ovarian cancer (HBOC), and is reported as a variant of English origin (Cybulski_2013, Meyer_2004, Varon_1998). The p.Lys233SerfsX5 variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 233 and leads to a premature stop codon at position 237. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the NBN gene are an established mechanism of disease in HBOC and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsJul 05, 2024The c.698_701delAACA pathogenic mutation, located in coding exon 6 of the NBN gene, results from a deletion of 4 nucleotides at nucleotide positions 698 to 701, causing a translational frameshift with a predicted alternate stop codon (p.K233Sfs*5). This alteration was detected in a series of individuals with Nijmegen breakage syndrome (NBS) (Varon R et al. Cell. 1998 May;93:467-76). This alteration has also been reported in a woman with bilateral breast cancer, multiple skin cancers, and a family history of cancer and a male patient with prostate cancer (Gass J et al. Fam. Cancer. 2017 Oct;16:551-553; Wu Y et al. Eur Urol Oncol. 2020 Apr;3(2):224-230). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs587780100; hg19: chr8-90983401; API